GlassScriptPhysician profile
Kyle William Savage
NPI 1508647280
$4,473.14
in general payments reported to CMS, 2019-2025
18 companies · $2,504 in 2025
The $2,504 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $131 · 2024: $1,838 · 2025: $2,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,473.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,472.76 | 2024-2025 | |
| Tonix Medicines, INC. | $447.36 | 2024-2025 | Zembrace Symtouch |
| Scilex Pharmaceuticals INC. | $445.53 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $408.52 | 2024-2025 | Contrave, Onzetra Xsail |
| Pfizer INC. | $314.66 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $276.17 | 2024-2025 | Ajovy |
| Axsome Therapeutics, INC. | $193.73 | 2025 | Symbravo |
| Lilly USA, LLC | $182.31 | 2023-2025 | Emgality, Reyvow, Zepbound |
| Lundbeck LLC | $179.94 | 2023-2025 | Vyepti |
| Ucb, INC. | $117.52 | 2023-2025 | Nayzilam |
| Impel Pharmaceuticals LLC | $93.37 | 2024 | Trudhesa |
| Eisai INC. | $81.97 | 2024-2025 | |
| Novo Nordisk INC | $64.36 | 2023-2025 | Wegovy |
| Amgen INC. | $59.46 | 2023-2024 | Aimovig |
| Averitas Pharma INC. | $43.54 | 2024-2025 | Qutenza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $42.97 | 2025 | Cobenfy |
| Ibsa Pharma INC. | $34.33 | 2024-2025 | Tirosint, Licart, Flector |
| Amneal Pharmaceuticals LLC | $14.64 | 2025 | Brekiya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Savage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.